XML 33 R21.htm IDEA: XBRL DOCUMENT v3.22.2
SHARE OPTION PLANS AND ESPP (Tables)
 6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement, Recognized Amount [Abstract]  
Schedule of Stock Option Plans
A summary of the status of the Company’s option plans as of June 30, 2022 and changes during the period then ended is presented below:
Six months ended June 30, 2022
Unaudited
Number
of options		Weighted
average
exercise
price
Outstanding at beginning of year8,549,322 $33.09 
Granted665,007 80.67 
Exercised(269,961)18.78 
Forfeited and canceled(68,591)79.17 
Outstanding as of June 30, 20228,875,777 $36.74 
Exercisable options7,189,164 $24.86 
Schedule of RSUs and PSUs
A summary of the status of the Company’s RSUs and PSUs as of June 30, 2022 and changes during the period then ended is presented below.
Six months ended June 30, 2022
Unaudited
Number
of RSU/PSUs		Weighted
average
grant date fair value
Unvested at beginning of year4,459,107 $65.56 
Granted1,104,033 81.04 
Vested(439,752)84.86 
Forfeited and cancelled(64,844)95.64 
Unvested as of June 30, 2022 (1)5,058,544 66.88 

(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones which are not probable, as of June 30, 2022, in accordance with ASC 718 as follows:
 June 30, 2022
Number of
PSUs		Fair value at grant date per PSUTotal fair value at grant date
2,703,852 $48.16 $130,218 
108,113 69.37 7,500 
124,701 $80.59 10,050 
17,712 84.68 1,500 
7,605 $87.66 667 
10,532 94.94 1,000 
189,626 $114.26 21,667 
3,162,141 $172,602 
Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model
The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. We assessed fair value using the following underlying assumptions: 
Six months ended June 30,Year ended December 31,
2021
20222021
UnauditedAudited
Stock Option Plans
Expected term (years)
5.33-5.83
5.50-6.00
5.50-6.00
Expected volatility
60%-62%
60%-62%
60%-63%
Risk-free interest rate
1.58%-3.04%
0.85%-1.02%
0.78%-1.27%
Dividend yield0.00 %0.00 %0.00 %
ESPP
Expected term (years)0.500.500.50
Expected volatility51.00 %54.00 %
54%-81%
Risk-free interest rate0.19 %0.09 %
0.05%-0.09%
Dividend yield0.00 %0.00 %0.00 %
Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and six months ended June 30, 2022 and 2021 and the year ended December 31, 2021 was:
Three months ended June 30,Six months ended June 30,Year ended December 31,
2021
2022202120222021
UnauditedUnauditedAudited
Cost of revenues$1,029 $827 $1,981 $1,560 $3,471 
Research, development and clinical studies7,624 8,505 14,425 13,629 27,597 
Sales and marketing6,802 6,429 13,457 10,900 22,673 
General and administrative10,368 12,120 21,005 20,655 41,159 
Total share-based compensation expense$25,823 $27,881 $50,868 $46,744 $94,900